MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products
Spanish Public-private Foundation for Life Sciences Research Adopts the Genedata Screener® 7.0 Data Management Platform for High Throughput and High Content Screening.
Basel, Switzerland, and Granada, Spain, December 9, 2009
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, and Fundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía), today announced their collaboration in the discovery of innovative medical compounds to fight infectious diseases, cancer and immune disorders. MEDINA has licensed the Genedata Screener platform - including the modules Condoseo for dose-response curve fitting and Kinetics Analyzer for the capture of time series data - for rapid and flexible data processing, management and analysis for all of their natural product screening and lead evaluation services. Those services span a wide range of assay technologies and instrumentation, from single-plate measurements to large-scale screens.
Fundación MEDINA has emerged from the Merck Sharp and Dohme (MSD) Basic Research Center in Madrid and houses comprehensive microbial collections and natural products libraries as well as a compound profiling platform for the identification of potential risks in cardiovascular safety and drug-drug interactions. Consequently, the MEDINA research teams need to master a multitude of screening technologies and set-up modifications on a daily basis, from anti-infective or biochemical inhibition assays to dose-response assay panels for the determination of potential compound risks.
"We received a clear vote from our users to go with Genedata," said Francisco Asensio, IT manager at Fundacion MEDINA. "The Screener system is unrivaled when it comes to the flexible and efficient integration of third-party infrastructure, and the easy templating for our complex assay setups impresses our screening teams just as much as it smoothes things out for our IT support people. As we inherited a large and disparate instrument park and built our entire organization from scratch, the need to align different technologies and research groups was a top priority."
"We are proud of our relationship with MEDINA," said Dr. Othmar Pfannes, CEO of Genedata. "Screener is an exceptional product thanks to its ability to master the breadth and complexity of today's screening scenarios. Introducing this product to the thriving Spanish life science market and establishing our presence there is an exciting challenge for Genedata. We are looking forward to a dynamic partnership with Fundación MEDINA and growing our business in Spain."
About Fundación MEDINA
Created in November 2008, Fundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía) is a non-profit public-private partnership between Merck Sharp and Dohme de Espana S.A. (MSD), the Junta de Andalucia and the University of Granada, Spain. MEDINA focuses on 1) the discovery of innovative compounds from microbial natural products to be licensed as new leads for development by industrial companies, and 2) ADME/TOX high throughput screening platform service for the evaluation of drug candidates. www.medinaandalucia.es
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, and Genedata Expressionist® make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. www.genedata.com
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.